Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
Horizon BCBS of New Jersey Launches Oncology Home Infusion Program | AMCP Nexus 2023
October 19th 2023Just over 160 patients have participated in the insurer's oncology home infusion program since it started in late 2020. Patient satisfaction is high, according to Horizon officials, who are looking to expand the program with other providers in its market and to include more drugs that patients could be treated with at home.
Read More
PBM Legislative Update: One Bill in the House, Three in the Senate | AMCP Nexus 2023
October 17th 2023Melissa Andel, M.P.P., of CommonHealth Solutions LLC, thumbnailed the four pieces of legislation advancing through Congress that would tighten regulation and oversight of pharmacy benefit managers (PBMs).
Read More
With Its Future in Doubt, One of the Architects Makes a Case for PEPFAR | IDWeek 2023
October 15th 2023Mark Dybul, M.D., the keynote speaker for the closing session of the IDWeek meeting in Boston, delivered an impassioned defense of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as its reauthorization by Congress has got ensnarled in abortion issues.
Read More
Cytomegalovirus Update: For the First Time, a Phase 3 Vaccine Trial | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center spoke about the phase 3 trial of Moderna’s mRNA vaccine against CMV and another candidate being developed by Merck that showed some promise in a phase 2B trial.
Read More
Cytomegalovirus Update: Why Isn’t There a Vaccine? | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says lack of awareness and funding as well as some characteristics of the virus itself have slowed development of vaccine against CMV.
Read More
Cytomegalovirus Update: Congenital CMV Is a ‘Disease of Disparity’ | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says the epidemiology of congenital CMV hasn’t varied much over the years and that the condition does disproportionately affect lower socioeconomic populations and communities of color in the U.S.
Read More
Cytomegalovirus Update: ‘CMV Is Like a Zika Epidemic, Times 10, Every Year’ | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says that as the most common infectious cause of long-term disability CMV should be the number one target of vaccine development.
Read More
Hepatitis B Treatment Eligibility Is Complicated. Time To Simplify It, Says Expert | IDWeek 2023
October 13th 2023Su Wang, M.D., M. P.H., of Cooperman Barnabas Medical Center says liberalizing and simplifying hepatitis B treatment guidelines would elevate patient-centered decision-making and help reduce transmission of the virus.
Read More
7 Things You Should Know About Opill, the First OTC Daily Oral Contraceptive
October 13th 2023Opill (norgestrel) is expected to be available early in 2024. Whether it truly broadens access to daily contraception will depend on Medicaid coverage, which is spotty, requirements under the ACA and pharmacist prescribing.
Read More
Billing and Reimbursement Prime Targets for AI in Healthcare | IDWeek 2023
October 12th 2023The chair of Harvard Medical School’s bioinformatics department says the deterministic, discrete data of billing and reimbursement means that artificial intelligence’s first big impact in healthcare is likely to be in “the business of healthcare.”
Read More
The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.
Read More
Gene Therapy for Hemophilia As a ‘Paradigm Shift’
September 28th 2023Roctavian for hemophilia A and Hemgenix for hemophilia B could spare some patients from treatment that involves intravenous infusions of clotting factors several times a week. But a hemophilia expert cautions that the high-priced gene therapies aren’t a cure and that the reprieve won’t last a lifetime.
Read More
Employer Group to Hospitals: Your High Prices Aren't Justified and Here's Why
September 20th 2023The National Alliance of Healthcare Purchaser Coalitions issued a report today debunking what it says are 10 myths used by hospitals to justify the high prices they charge health plans sponsored by employers. The American Hospital Association responded with a statement that said report was a rehash of anti-hospital talking points.
Read More